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Abstract
Purpose Several new gene mutations have been reported in
recent years to be associated with a risk of familial pheo-
chromocytoma. However, it is unclear as to whether
extensive genetic testing is required in all patients.
Methods The clinical data of consecutive patients operated
for pheochromocytoma over a decade in a tertiary referral
center were reviewed. Genetic screening was performed
using a 10-gene panel: RET, VHL, SDHB, SDHD, SDHA,
SDHC, SDHAF2, MAX, TMEM127 and FH.
Results A total of 166 patients were analyzed: 87 of them
had genetic screening performed (39 M: 44.8%, 48 F:
55.2%, age range 6–81 years, mean 45±16.8 years). In
total, 22/87 (25.3%) patients had germline mutations, while
65/87 (74.7%) patients presented with apparently sporadic
tumors. Germline VHL mutations were identified in 11.7%
of patients, RET in 6.8% (five MEN2A/MEN2 and one
MEN2B/MEN3), SDHD in 2.3%, MAX in 2.3%, SDHB in
1.1%, and TMEM127 in 1.1% of patients. At diagnosis,
15.1% of patients with unilateral non-syndromic pheo-
chromocytoma showed germline mutations. We identified
19.7% of mutations in patients with unilateral-non-recurrent
pheochromocytomas within 5 years vs. 50% in the
recurrent-bilateral-metastatic group (p= 0.01). Germline
mutations were more frequently seen with bilateral pheo-
chromocytomas (p= 0.001): 80% of patients with bilateral
disease had germline mutations (4 VHL, 3 RET, 1 MAX).
Conclusions The advent of rapid genetic screening using a
gene-panel makes it feasible to screen large cohorts of
patients and provides a valuable tool to contribute to the
prediction of bilateral and malignant disease and to screen
family members.
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Introduction
Pheochromocytoma (PHEO) is a rare neuroendocrine tumor
(NET) arising from the adrenal chromaffin cells of the
embryonic neural crest. Extra-adrenal PHEOs are referred
to as paragangliomas (PGLs). PHEOs have an annual
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incidence of 1–4/106 population [1], and are a significant
albeit rare cause of hypertension, accounting for approxi-
mately 0.1 to 1% of patients with hypertension [1–4].
Despite their low frequency, PHEOs represent a significant
challenge to clinicians as they can be lethal if untreated but
can be subject to long-term cure, in the majority of cases, if
diagnosed at an early stage and treated surgically.
The clinical presentation of the disease shows huge
variability, with frequently non-specific symptoms and
often mimicking other clinical conditions. The symptoms
are usually secondary to the effects of high circulating
catecholamines: hormonal hypersecretion can lead to
hypertension, headaches, palpitations, diaphoresis, pallor,
anxiety, and panic attacks [5].
Previously, PHEOs were thought to be associated with
germline mutations in less than 10% of cases, the majority
of these presenting with clear syndromic features. More
recently it has been shown that up to 40% of PHEO are
associated with an inherited mutation [6–9]. These are
particularly present in younger patients, and those with
multiple tumors [10], but may occur in patients with
apparently simple sporadic tumors with no other syndromic
features and no family history [11]. Currently, many dif-
ferent PHEO susceptibility genes have been reported: NF1
[12, 13], RET [13], VHL [14], SDHD [15], SDHC [16],
SDHB [17], EGLN1/PHD2 [18, 19], KIF1 [19], SDH5/
SDHAF2 [20], IDH1 [21], TMEM127 [22], SDHA [23],
MAX [24], FH and HIF2 [25], with new ones being added
annually. On this basis, contemporary guidelines suggest
that in the management of a patient with a PHEO, it is
essential to consider genetic testing because of the high
frequency of PHEOs associated with germline mutations
[26].This is based on the high frequency of recurrent and
malignant disease with some mutations, especially in SDHB
[26–28], and because diagnosing a hereditary syndrome in
the proband could lead to earlier diagnosis and treatment of
PHEOs, and other syndromic manifestations in relatives
[28–30]. Nevertheless, current recommendations that
genetic testing should be considered in each patient do not
imply that genetic testing should be performed in all
patients. Indeed, genetic testing has been considered to have
limited incremental value in patients with no family history,
no syndromic or malignant features, and with unilateral
disease. The importance of the diagnosis of an inherited
disease for at-risk families must be balanced against any
negative impacts and the financial costs of genetic testing.
Thus, recent guidelines recommend the use of a diagnostic
algorithm driven by clinical aspects to evaluate the priorities
for specific sequential genetic testing in PHEO patients with
suspected germline mutations, proposing a selection of
genes to be tested prioritized according to a syndromic or
metastatic presentation [29]. Young age at presentation,
positive family history, and the presence of multifocal
PHEO or bilateral adrenal tumors are also recognized as
reasons for prioritizing patients for testing. Furthermore,
tumor location and type of catecholamine secreted may also
guide selection of suitable genes to test [29].
In this context, we utilized an alternative approach in
which a 10-gene panel has been used to investigate the
possibility of a germline syndrome in all patients presenting
with PHEOs. The aim of this study was to evaluate whether
such single extensive genetic testing is a valuable alter-
native approach to such patients. We have not included
patients with PGLs as these are known to have a higher
germline mutation rate.
Methods
Patients
Consecutive unselected patients operated in a tertiary
referral centre between 2000 an 2015 were considered for
inclusion in the study. Full genetic screening was performed
in patients diagnosed after 2013 if this had not already been
requested.
Patients operated before 2013 were invited for genetic
screening if genetic testing had either not been performed or
was incomplete. Of this subgroup, 65 patients who had not
had any genetic screening performed at diagnosis or during
early follow-up, recall for genetic testing was unsuccessful
due to either inability to contact the patients, or the fact that
they had moved region and the distance was too far to
travel.
Moreover, of the 101 patients that had genetic testing, in
14 patients only a single gene was analyzed before the
PHEO was diagnosed because of the typical clinical fea-
tures of the suspected disease or for familial disease. Con-
sidering that in these patients genetic mutations were
discovered before the diagnosis of a PHEO, we decided to
exclude them from analysis (Fig. 1).
Therefore, 87 patients were screened, but for 8 there
were syndromic reasons to identify a single gene, which
then proved positive, while partial screening was only
possible in a further 13 as the patients were unable to return
for complete screening, which was thus only partial in these
patients.
The diagnosis was based on elevated plasma and/or
urinary metanephrines (MTs) and abnormal imaging, and
then confirmed by histology. For more detailed evaluation
of trends, changes, and outcomes, we divided our patients
into two main subgroups: children (6–18 years) and adults
(19 years and older). The adult group was again divided into
two subcategories: (a) young adults (19–45 years), (b) older
adults (over 45 years).
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Genetics of PHEOs
Genetic testing for mutations in principal PHEO suscept-
ibility genes (RET, VHL, SDHB, SDHD, SDHA, SDHC,
SDHAF2, MAX, TMEM127, and FH) was performed at the
Oxford Medical Genetics Laboratories, Oxford University
Hospitals NHS Trust, Churchill Hospital. NF1 was not tested
as the diagnosis would have been made on clinical grounds.
Genomic DNA was extracted from peripheral blood
leukocytes using standard procedures, and subjected to
Sanger sequencing of the coding regions and exon-intron
boundaries (+/−10 nt) of VHL, SDHB, SDHD, SDHA,
SDHC, SDHAF2, MAX, TMEM127 and FH, plus targetted
analysis of exons 10 and 11 of RET. Sanger sequencing was
performed using the ABI BigDye 3.1 Terminator Cycle kit
(Applied Biosystems), and analyzed using an ABI 3100
(Applied Biosystems) and mutation surveyor software
(SoftGenetics). Additionally, analysis for deletions or
duplications involving SDHB, SDHD, SDHAF2, SDHC and
VHL was undertaken by multiplex ligation-dependent probe
amplification (MRC Holland kits P226-C1 and P016-C2).
In 13 patients, there was only partial genetic screening
performed according to the gene tests available at the time
of operation because of inability to contact the patients or
because they were unable to attend the Department to
complete the genetic screening because they had moved
region and the distance was too far to travel.
Biochemical testing and diagnosis
The biochemical phenotype of the tumors was based on
increased MTs [normetanephrine (NMT) or MT] in plasma
and/or urine, as well as on plasma and/or urine 3-
methoxytyramine (3MT), when available. Twenty-four-
hour urinary MTs, NMT, MT and 3MT were analyzed by
liquid chromatography–mass spectrometry (LC-MS) and
for 2013–2016 by LC-MS/MS: the reference values were
identical. Urinary MTs measured showed an inter-assay
imprecision of 6.58% at 0.56 μmol/24 h, 6.13% at 2.99
μmol/24 h for normetadrenaline; 8.28% at 1.96 μmol/24 h,
6.93% at 7.68 μmol/24 h for metadrenaline and of 11.27%
Fig. 1 Flow chart of requested genetic screening
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at 0.51 μmol/24 h, 8.30% at 2.6 μmol/24 h for 3MT. Plasma
MTs were analyzed by LC-MS/MS.
The confirmation of the diagnosis of a metastatic PHEO
was based on the clinical presentation and positive bio-
chemistry/radiology or histopathological examination of
tumors, and a previous history of PHEO. Positivity on
PHEO-specific functional imaging studies further supported
the diagnosis of metastatic PHEO, when available.
Localization of the primary tumor and metastases
Tumor presence was detected by CT and/or MRI of the
abdomen or total-body CT in case of incidental findings.
The majority of the patients (57/87: 65.5%) underwent also
123I-MIBG scintigraphy to confirm a suspicious lesion and/
or to explore the presence of metastatic disease, and a very
small number 18FDG-PET (5/87: 5.7%).
Follow-up
Patients were usually followed-up initially every 6 months
then yearly, unless other problems supervened, while meta-
static patients were followed-up more frequently depending
on clinical/biochemical/radiological evaluations followed by
treatment recommendations and/or follow-up plans.
Of these patients, 61 underwent regular follow-up in our
outpatient clinic with a minimum follow-up of 12 months
and a maximum follow-up of 144 months.
Statistical methods
Data presented are expressed as means± standard devia-
tions (SD) for continuous variables and as counts (%) for
categorical variables. For comparisons of single variables, t-
tests were used while, for analyses involving multiple
comparisons, the one-way analysis of variance or, for non-
parametric data, the Mann–Whitney test, were used to
determine statistical significance. Frequencies were com-
pared using the χ2 test. p< 0.05 was considered indicative
of a statistically significant difference. Statistical analyses
were performed using SPSS (version 17, Chicago, IL,
USA).
The study was registered as an Audit Project by the
Oxford University Hospitals Trust (Datix ID number 4061).
Results
Characteristics of the study population
Of the patients with PHEOs, 39/87 (44.8%) were males and
48/87 (55.2%) females. The mean age at diagnosis was 45
± 16.8 years (range: 6–81 years): 72/87 (82.8%) underwent
laparoscopic adrenalectomy, 12/87(13.8%) open and 3/87
(3.4%) laparoscopic-converted-to-open adrenalectomy.
Over a median follow-up of 50.4 months, there were 71/
87 patients (81.6%) with solitary tumors, 10/87 (11.5%)
showed bilateral PHEO of which three were also recurrent,
two were also metastatic and one both metastatic and
recurrent; 8/87 patients (9.2%) had recurrent PHEO of
which four were metastatic, three bilateral and one
both metastatic and bilateral, and 9/87 patients (10.3%)
had metastatic tumors of which four were recurrent,
two bilateral and one both recurrent and bilateral. Moreover,
9/87 showed another NET associated with PHEO, specifi-
cally five medullary thyroid carcinomas, three NETs of the
pancreas and one bronchial carcinoid. In addition,
2/87 presented a non-NET tumor not clearly associated
with known syndromes (one testicular tumor and one
lymphoma).
Dividing by age subgroups : in those under 18 years of
age 4/6 (66.6%) had solitary tumors, 1/6 (16.7%) had
bilateral disease, 1/6 (16.7%) had bilateral and recurrent,
while none had metastatic disease. In the subgroup
18–45 years, 34/43 (79.1%) had solitary tumors, two
bilateral (4.7%), one metastatic (2.3%), two bilateral and
recurrent (4.7%), three with recurrence and metastases
(7%), and one bilateral and metastatic (2.3%). In the sub-
group of patients older than 45 years, 33/38 (86.8%) had
solitary tumors, one bilateral (2.6%), one metastatic (2.6%),
one bilateral and metastatic (2.6%), one with recurrence and
metastases (2.6%), and one bilateral, recurrent and meta-
static (2.6%).
Considering all patients younger than 45 years of age,
38/49 (77.7%) had solitary tumors, three bilateral (6.1%),
one metastatic (2%), three bilateral and recurrent (6.1%),
three with recurrence and metastases (6.1%), and one
bilateral and metastatic (2%).
Characteristics of lesions at diagnosis/surgery
At diagnosis/surgery of the primary tumor, three patients
had metastatic disease, one patient was 33 years old and had
liver and bone metastases, and showed a RET mutation; one
patients was 41 years old and had a metastasis behind the
vena cava, and his genetic screening for the panel of 10
genes analyzed was negative; the third was 36 years old,
had bone metastases and his genetic screening for the panel
of 10 genes analyzed was negative.
Four patients had bilateral disease at diagnosis/surgery:
one patient was 25 years old and showed a VHL mutation,
one patient was 33 years old, showed a RET mutation and
had metastatic disease from the diagnosis, one patient was
36 years old and had an NF1 mutation, one patient was 56
years old and showed a MAX mutation.
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Hereditary and apparently sporadic PHEO
Overall, 87 patients underwent genetic screening, with 22/
87 (25.3%) patients demonstrating germline mutations
diagnosed on the gene panel. Specifically, germline muta-
tions were identified in 10 (11.7%) patients for VHL
mutations, six (6.8%) for RET (5 MEN2A/MEN2 and one
MEN2B/MEN3), two (2.3%) for SDHD, two (2.3%)
patients for MAX, and one each for SDHB and for TMEM-
127. Moreover, in 6 patients NF1 was diagnosed based on
clinical grounds (Fig. 2).
Dividing by age subgroups
In the group of pediatric patients (<18 years), 4/6 (66.7%)
had germline mutations; 15/43 (34.9%) in the 18–45 year
subgroup and 3/38 (7.9%) in the older subgroup (>45 years)
(p= 0.001 comparing children vs. older adults and p= 0.003
comparing young adults vs. older adults). The younger
patients showed a significantly higher percentage of muta-
tions compared to the older patients (43.4% vs. 12.5%, p=
0.001 when comparing patients <45 to patients ≥45 years
old). In the pediatric subgroup, all the four patients with
positive genetic screening showed a VHL mutation. In the
young adult subgroup (18–44 years), five subjects showed
VHL mutations, five RET mutation (four MEN 2A and one
MEN 2B), two patients SDHD mutations, one patient SDHB
mutation, one patient showed a MAX mutation and one
patient a TMEM127mutation. In the older adults subgroup (≥
45 years old), one subject showed a VHL mutation, one a
RET mutation compatible with MEN 2A and one patient
showed a MAX mutation (Table 1 and Table 2).
Dividing by new events of pheo
Fourteen mutations were diagnosed in the 71 patients with
unilateral-non-recurrent PHEOs (within 5 years) (19.7%)
vs. 8/16 (50%) in the recurrent-bilateral-metastatic group
(p= 0.01).
Mutations were more frequently seen with bilateral 8/10
(80%) compared to unilateral PHEOs 14/77 (18.1%) (p=
0.001). In particular, in patients with bilateral disease the
distribution of germline mutations were as follows: 4VHL,
3 RET, 1 MAX.
Dividing by the presence of other tumors associated with
PHEOs
Germline mutations were identified with a higher frequency
in patients with PHEOs who also developed other NETs
excluding PGLs compared to patients without evidence of
NETs during the follow-up period (7/8:87.5% vs. 15/
79:19% p= 0.001). As a retrospective survey, follow-up
was not standardised but was decided by individual clin-
icians: however, this was usually every 3–6 months, with a
maximum time of 12 months.
No differences were observed when we compared
patients with PHEOs associated with a tumor of neu-
roendocrine origin and patients with a tumor not of neu-
roendocrine origin.
Age-related characteristics of primary and metastatic
PHEOS
The overall mean age of patients at the time of the diagnosis
of the primary tumor was 45± 16.8 years (range 6–81
years). The mean age at initial diagnosis was significantly
different when grouped by germline mutation. Patients with
any identified germline mutation were younger at diagnosis
than those without an identified mutation (32.9 ± 16.2 years
vs. 49± 15.1 years p= 0.001).
In the recurrent-bilateral-metastatic group, comparing
patients with genetic mutations and without genetic muta-
tions, patients were significantly younger at the time of
diagnosis of the primary tumor in the first group
(27.9 ± 14.3 years vs. 49.8± 13.2 years p= 0.007).
The mean time interval to appearance of metastases was
Fig. 2 Distribution of genetic mutations in the study population
(included NF1 mutations diagnosed on clinical grounds)
Table 1 Germline mutation rates in different age subgroups
Mutation n <18 years 18–44 years >45 years
MAX 2 1/43 (2.3%) 1/38 (2.6%)
RET 6 5/43 (11.6%) 1/38 (2.6%)
SDHB 1 1/43 (2.3%)
SDHD 2 2/43 (4.6%)
TMEM-127 1 1/43 (2.3%)
VHL 10 4/6 (66.7%) 5/43 (11.6%) 1/38 (2.6%)
No mutation
identified
65 2/6 (33.3%) 28/43 (65.3%) 35/38 (92.2%)
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24.2± 49.3 months (range 12–144 months) and the
mean age at first metastases 46.5± 10.9 years (range
33–61 years).
Sporadic PHEOs and asymptomatic patients at
diagnosis
Considering patients with sporadic PHEOs, with no asso-
ciated syndrome and without any family history for PHEOs
at the time of diagnosis of the disease, 11/73(15.1%)
showed genetic mutations: three RET (two MEN2A and one
MEN2B), two VHL, two MAX, two SDHD, one SDHB and
one TMEM127.
Of interest is the fact that in our population 16/87
(18.3%), patients were ‘incidentally diagnosed’ to have a
PHEO, without any symptoms or signs typical of a PHEO
and not in the context of any syndromic condition: two of
these (2/16: 12.5%) showed genetic mutations, one SDHB
and one TMEM127.
Discussion
Genetic screening has previously been considered to be
expensive and time-consuming, but there are important
implications of having a genetic diagnosis in apparently
sporadic PHEOs. According to the American Society of
Clinical Oncology’s general recommendations for genetic
screening [31], all patients with a risk of at least 10% of
carrying a genetic mutation should be offered genetic test-
ing, especially when the results would aid in diagnosis or
influence the management of the patient or family members
at hereditary risk of cancer [32]. In the present study, we
have confirmed that more than 25% of patients with PHEOs
showed germline mutations [5, 33], and that the rate can be
as high as 55% if diagnosed by 18 years of age, as pre-
viously reported [5]. At the time of diagnosis of the primary
tumor, patients were significantly younger in the group with
genetic mutations compared to the group without genetic
mutations. Moreover, in the recurrent-bilateral-metastatic
group, the age of patients at the time of the diagnosis of
primary tumor was significantly lower in patients with
genetic mutations compared to patients without mutations.
These data suggest that many patients with PHEOs should
have genetic testing, especially when diagnosed at a young
age. Furthermore, overall, in our study 15.1% of patients
with apparently sporadic PHEOs and no family history
showed genetic mutations, with a broad mix of differing
aetiologies in line with the prevalence reported in a recent
meta-analysis [34]. This high rate, plus the fact that there
were varying genetic mutations, supports the use of a gene
panel as opposed to algorithmic targeting of single genes
sequentially.
Interestingly, in this population a high proportion of
patients (18.3%) were ‘incidentally diagnosed’ to have a
PHEO, without any symptoms or signs typical of a PHEO
and not in the context of any syndromic condition, and
12.5% of them showed germline mutations. These results
suggest that the risk of a germline mutation is also sig-
nificant in this group of lesions that are usually considered
more indolent, and that proper and prompt genetic screening
is essential, allowing the appropriate management and
leading to a more accurate prognosis.
In our population, 50% of germline mutations were
identified in patients with recurrent-bilateral-metastatic
disease compared to 19.7% in the unilateral-non-recurrent
PHEOs, suggesting that having a germline mutation
increases the risk to develop a more complex disease, such
as a recurrent or bilateral or a metastatic PHEO. In these
patients, genetic screening is of particular value because it
allows the clinician to provide a more focused management
and follow-up of such patients at high risk of further
disease.
We currently use a 10-gene panel analyzed with Sanger
sequencing, rather than individual reporting for each gene
according to other clinical or biochemical features as this is
relatively cheap, efficient and, in pure cost terms, little
different to a single gene assessment. Furthermore, NGS
Table 2 Age at diagnosis and
sex distribution for different
mutation groups within PHEO
patients
Mutation n Age at diagnosis, mean± SD, (min-
max)
Sex M n(%), F n(%)
MAX 2 50± 8.5 (44–56) F 2/2 (100%)
RET 6 37.3± 17.5 (19–69) M 2/6 (33.3%) F 4/6 (66.7%)
SDHB 1 22 M 1/1 100%
SDHD 2 39± 4.2 (36–42) M 2/2 100%
TMEM-127 1 45 M 1/1 100%
VHL 10 26.7± 16.3(6–55) M 5/10 (50%) F 5/10 (50%)
No mutation
identified
65 49.1± 15 (18–81) M 29/65 (44.6%) F 36/65 (55.4%)
M male, F female
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(next-generation sequencing) has been recently validated
increasing the detection of germline mutations in patients
with PHEO, reducing processing time, time taken to report
a result to a clinician, and lowering the cost compared to the
conventional Sanger sequencing [35]. The use of a wide
genetic panel appears to be especially appropriate for PHEO
as even when there is no specific indication of a familial
condition, with a unilateral non-recurrent PHEO, the
germline mutation rate was still markedly above 10%. This
rate is somewhat above that reported in a recent meta-
analysis [34], but similar to a NGS study [36] and is in
accord with new recommendations [37].
Limitations
The principal limitations of this study are the relatively
small sample size, even though collected from a major
center over a prolonged period, with the lack of a consistent
group of patients with mutations that were not in the context
of a syndromic condition. Moreover, one of the main lim-
itations is the retrospective nature of data collection in the
majority of patients and our own institutional referral bias
that may lead to a potential positive selection bias that may
over-estimate the prevalence rate of more aggressive
PHEOs. Furthermore, the gene panel was expanded over
time, and even though we attempted to retrospectively re-
analyze for germline mutations for previously-operated
patients, in some instances this was not logistically possible.
However, we act as a major referral centre for PHEOs in the
context of the availability of experienced laparoscopic sur-
gery. It is therefore likely the high rate of germline muta-
tions seen in patients with apparently sporadic tumors,
especially in younger patients and in the absence of a family
history, is probably broadly representative of patients pre-
senting to any major specialist unit.
Conclusions
While rare, PHEOs are more commonly associated with
germline mutations than any other solid tumor type. Due to
the advent of rapid genetic screening for a wide gene panel,
more patients and families are being identified as mutation
carriers and require lifelong screening for these potentially
life-threatening tumors. The identification of a germline
mutation in a patient with an apparent sporadic PHEO could
lead to the early diagnosis of multiple or more aggressive
tumors or additional syndromic neoplasms in the patient, as
well as in relatives at risk. Knowledge of the heritable
mutation has important implications for surveillance and
monitoring of probands and their family members, and we
believe multi-gene screening should become part of routine
care for patients with PHEOs, especially as the costs of such
screening fall.
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